MaxCyte
Gaithersburg
About MaxCyte
MaxCyte specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes of therapeutics for a range of chronic and acute diseases. It provides MaxCyte STX, a scalable transfection system for the scalable and reagent-free (co) transfection of primary cells, stem cells, and cell lines involved in the areas of cell-based assays for content screening, preclinical protein production, and small molecule.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $30.5M
- Funding stage: IPO
- Last round: Series Unknown (Dec 2014)
- Ticker: lse:MXCT
- Website: maxcyte.com
- Phone: (301)944-1622
Industries & Categories
Biotechnology, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/maxcyte-65464 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.